Scientific Publications

Advancing dermatological science.

October 2022

JAMA

Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis The DERMIS-1 and DERMIS-2 Randomized Clinical Trials
Read More

September 2022

EADV 2022

Efficacy and safety of roflumilast foam 0.3% in patients with seborrheic dermatitis in a phase 3 trial
Read More

September 2022

EADV 2022

Long-term Safety and Efficacy of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a 24–52-week, Open-label Phase 2 Trial
Read More

September 2022

EADV 2022

Efficacy and Tolerability of Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis Involvement on the Face, Intertriginous, or Genital Areas: Pooled Results from Phase 3 Trials (DERMIS-1 and DERMIS-2)
Read More

September 2022

EADV 2022

Efficacy and Safety by Race and Ethnicity in a Randomized, Double-blind, Vehicle-Controlled, Phase 2a Study Evaluating Once-Daily Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis
Read More

September 2022

EADV

Efficacy and Safety by Race and Ethnicity in a Randomized, Double-blind, Vehicle-Controlled, Phase 2a Study Evaluating Once-Daily Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis
Read More

April 2022

AMCP 2022

Effects of Roflumilast Cream on Patient Burden and Work Productivity in Patients With Psoriasis
Read More

April 2022

AAD 2022

Pooled Efficacy and Safety Results From the DERMIS-1 and DERMIS-2 Phase 3 Trials of Once-Daily Roflumilast Cream 0.3% by Baseline Body Surface Area
Read More

April 2022

AAD 2022

Pooled Efficacy and Safety Results From the DERMIS-1 and DERMIS-2 Phase 3 Trials of Once-Daily Roflumilast Cream 0.3% for Treatment of Chronic Plaque Psoriasis
Read More

April 2022

AAD 2022

Efficacy and Safety of Once-Daily Roflumilast Cream 0.3% in Patients With Knee/Elbow Involvement: Pooled Results From Phase 3 Trials (DERMIS-1 and DERMIS-2)
Read More

April 2022

AAD 2022

Long-term Safety and Efficacy of Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis: Interim Results From a 24-Week, Phase 3 Open-Label Study
Read More

April 2022

AAD 2022

Effect of Roflumilast Foam 0.3% Treatment of Seborrheic Dermatitis on Patient Quality of Life: Results From a Phase 2 Study
Read More

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download
You are leaving Arcutis.com.

This link will send you to a site maintained by an independent third party.
Arcutis is not responsible for the content on that site.

Cancel Continue